1. Pink Sheet

US FDA Urges Generics To Stay Engaged On Metered Dose Inhalers

 
• By Michael McCaughan

As the generic drug industry warily watches another transition process for propellants in metered-dose inhalers, the US FDA is urging companies not to discontinue development because they are afraid of being caught in the switch.

The FDA will work with generic sponsors developing metered-dose inhalers with LGWP propellant. (Shutterstock)
Key Takeaways
  • Generic drug companies may worry about transitioning metered dose inhaler products to new lower global warming potential propellants, but the FDA stressed they should continue product development.

The US Food and Drug Administration wants generic drug companies to continue working on metered dose inhaler (MDI) products amid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from R&D